Supplementary Files
Keywords
Aldosteronism
Screening
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To address aspects related to primary aldosteronism (HAP) screening and discuss the necessity to cover all newly diagnosed hypertensive patients. Bibliographic Review: The HAP have a high prevalence and two main subtypes. It’s relation to bad cardiovascular outcomes is proven and much higher when compared to primary hypertension. The screening is an important strategy, since that the direct treatment can improve blood pressure, reduce cardiovascular risk, sometimes even achieve cure in surgical treatment, and improve biochemical profile. Thus, considering the factors mentioned and the cost-effectiveness involved, it is important that screening the entire population of hypertensive patients be considered in clinical practice. Final Considerations: Although the indications of screening for HAP have predetermined groups of patients, given their elevated risk, this work shows that the screening can be extended to all newly diagnosed hypertension, given the cost-effectiveness, high morbidity and mortality related and high prevalence of HAP among hypertensive patients.
References
LUBITZ CC, et al. Cost-Effectiveness of Screening for Primary Aldosteronism and Subtype Diagnosis in the Resistant Hypertensive Patients. Circ Cardiovasc Qual Outcomes, 2015; 8(6): 621-630.
YAMASHITA T, et al. Combination of urine pH and female gender for screening primary aldosteronism in newly diagnosed hypertensive patients. Nephrology Dialysis Transplantation, 2015; 30(3): iii92–iii101.
HANNEMANN A, et al. Screening for primary aldosteronism in hypertensive subjects: results from two German epidemiological studies. European Journal of Endocrinology, 2012; 167(1): 7–15.
JANSEN PM, et al. Aldosterone-to-renin ratio as a screening test for primary aldosteronism – the Dutch ARRAT Study. Netherlands The Journal of Medicine, 2008; 66(5): 220-228.
WEICKERT MO, et al. A reverse postural test as a screening tool for aldosterone-producing adenoma: a pilot study. Endocrine, 2009; 36(1): 75–82.
TOMASCHITZ A, PILZ S. Aldosterone to Renin Ratio – A Reliable Screening Tool for Primary Aldosteronism? Horm Metab Res, 2010; 42(6): 382–391.
WIDIMSKY J, et al. Prevalence of Primary Aldosteronism in a General Population Sample of Hypertensive Subjects. The Czech Post-Monica Study. Journal of Hypertension, 2019; 37(1): e219.
JAFFE G, et al. Screening Rates for Primary Aldosteronism in Resistant Hypertension: A Cohort Study. Hypertension, 2020; 75(3): 650-659.
KATER CE. Hiperaldosteronismo Primário. Arq Bras Endocrinol Metab, 2002; 46(1): 106-115.
FUNDER JW, et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab, 2016; 101(5): 1889-1916.
VILELA LAP, ALMEIDA MQ. Diagnosis and Management of primary aldosteronism. Arch Endocrinol Metab, 2017; 61(3): 305-312.
ROSSI GP. Primary Aldosteronism: JACC State-of-the-Art Review. J Am Coll Cardiol, 2019; 74(22): 2799-2811.
MONTORI VM, et al. Validity of the Aldosterone-Renin Ratio Used to Screen for Primary Aldosteronism. Mayo Clin Proc, 2001; 76(9): 877-882.
KLINE GA, et al. The Potential Role of Primary Care in Case Detection/ Screening of Primary Aldosteronism. American Journal of Hypertension, 2017; 30(12): 1147-1150.
SCHWARTZ GL, et al. Screening for Primary Aldosteronism: Implications of an Increased Plasma Aldosterone/Renin Ratio. Clinical Chemistry, 2002; 48(11): 1919-1923.
GURGENCI T, et al. Screening for Primary Aldosteronism – How to adjust existing antihypertensive medications to avoid diagnostic errors. Australian Journal of General Practice, 2020; 49(3): 127-131.
SCHWARTZ GL, TURNER ST. Screening for Primary Aldosteronism in Essential Hypertension: Diagnostic Accuracy of the Ratio of Plasma Aldosterone Concentration to Plasma Renin Activity. Clinical Chemistry, 2005; 51(2): 386-394.
VOLPE C, et al. Screening for primary aldosteronism in a primary care unit. Journal of the Renin-Angiotensin- Aldosterone System, 2013; 14(3) 212–219.
STOWASSER M. Primary Aldosteronism; Epidemiology and Screening. Encyclopedia of Endocrine Diseases. 2nd ed. Elsevier, 2019; 598-606.
MONTICONE S, et al. Primary Aldosteronism: Who Should be Screened?. Horm Metab Res, 2012; 44(3): 163-169.
WIDIMSKY J, et al. Primary aldosteronism in a general population sample. The Czech post-MONICA study. Blood Pressure, 2020; 29(3): 191-198.
YAMASHITA T, et al. Screening of primary aldosteronism by clinical features and daily laboratory tests: combination of urine pH, sex, and serum K. J Hypertens, 2018; 36(2): 326-334.
WILLIAMS TA, REINCKE M. Diagnosis and management of primary aldosteronism: the Endocrine Society guideline 2016 revisited. European Journal of Endocrinology, 2018; 179(1): 19-29.
ROSSI GP, et al. The 2020 Italian Society of Arterial Hypertension (SIIA) practical guidelines for the management of primary aldosteronism. International Journal of Cardiology Hypertension, 2020; 15(5): 100029.
CAPELETTI JT, et al. Hiperaldosteronismo primário: diagnóstico e complicações clínicas. Rev Bras Hipertens, 2009; 16(1): 65-58.
MULATERO P, et al. Guidelines for primary aldosteronism: Uptake by primary care physicians in Europe. Journal of Hypertension, 2016; 34(11): 2253-2257.
NISHIKAWA T, et al. Guidelines for the diagnosis and treatment of primary aldosteronism – The Japan Endocrine Society 2009. Endocrine Journal, 2011; 58(9): 711-721.
BARROSO WKS, et al. Diretriz Brasileira de Hipertensão Arterial – 2020. Arq Bras Cardiol, 2021; 116(3): 516-658.